Serina Therapeutics' SER-252 to Enter Clinical Trials for Advanced Parkinson's Disease
核心洞察
Serina Therapeutics' SER-252, a novel apomorphine therapy, is set to begin Phase 1 clinical trials in the second half of 2025 for advanced Parkinson's disease (搜索).
SER-252 utilizes Serina's POZ Platform (搜索) for continuous dopaminergic stimulation, aiming to reduce motor complications and improve 'on time' for patients.
Serina Therapeutics secured a $5 million tranche of equity financing, strengthening its financial position to advance SER-252 into human studies.
Serina Therapeutics is advancing its lead program, SER-252, towards clinical trials as a potential breakthrough treatment for advanced Parkinson's disease (搜索). The Phase 1 trial is scheduled to begin in the second half of 2025.
SER-252: A Novel Approach to Parkinson's Treatment
SER-252 is an investigational apomorphine therapy leveraging Serina's proprietary POZ Platform (搜索) technology. This platform is designed to provide continuous dopaminergic stimulation (CDS), which has demonstrated the ability to mitigate levodopa-related motor complications such as dyskinesia. CDS also aims to increase 'on time' while reducing 'off time' for patients with advanced Parkinson's disease (搜索).
Steve Ledger, CEO of Serina Therapeutics, stated, "With a differentiated approach to continuous dopaminergic stimulation and an innovative drug delivery system, we believe SER-252 has the potential to provide meaningful benefits for patients with Advanced Parkinson’s disease."
The POZ Platform: Enhancing Drug Delivery
The POZ Platform (搜索) is based on a synthetic, water-soluble polymer called poly(2-oxazoline). This technology allows for greater control over drug loading and precision in the release rate of drugs delivered via subcutaneous injection. Serina believes that the POZ technology can help maintain more desirable and stable drug levels in the blood, particularly for drugs with narrow therapeutic windows.
Financial Backing for Clinical Advancement
Serina Therapeutics recently secured the second $5 million tranche of its $10 million equity financing with JuvVentures (UK) Limited. This funding is earmarked to support the advancement of SER-252 into Phase 1 clinical trials. At closing, Serina issued 500,000 shares of common stock at $10 per share, representing a 113% premium to the closing price on January 31, 2025. Additionally, Serina issued warrants to JuvVentures for up to 755,728 shares of common stock at an exercise price of $18.00 per share.
Enable Injections Partnership
SER-252 will utilize Enable Injections’ enFuse™ wearable drug delivery platform to enhance patient comfort and convenience. This platform provides CDS to patients via an easy-to-administer, long-acting subcutaneous injection, designed to minimize skin reactions.
About Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug product candidates for neurological diseases and other indications. The company's POZ Platform (搜索) aims to improve the efficacy and safety profiles of various modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.